PET concerns in bevacizumab treatment

Abstract

To the editor: In the recent article by Willett et al.1 on neoadjuvant therapy with bevacizumab (BV) in patients with rectal cancer, treatment effects were ascribed to therapy with the VEGF-specific antibody bevacizumab. However, because patients underwent concurrent treatment with 5-fluorouracil, we wonder if at least a portion of the treatment effects… (More)
DOI: 10.1038/nm0604-561a

Topics

1 Figure or Table

Slides referencing similar topics